Rocket Pharmaceuticals said it aligned with the FDA on continued enrollment, dosing, and key elements of the RP-A501 pivotal Phase 2 study, supporting the trial's ability to move forward.
Rocket Pharmaceuticals said it aligned with the FDA on RP-A501 trial design. That agreement clears key trial elements and supports continued enrollment and dosing for the pivotal study.
Follow Rocket Pharmaceuticals, Inc. (RCKT) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for RCKT